Therefore, it is not surprising that HELLS upregulation and overexpression in osteosarcoma is not restricted to RB1-null cases, but rather a generalized event observed across samples that bear RB-E2F pathway inactivation. The gene discussed is HELLS; the disease is osteosarcoma.